Pharmaceutical Technology10h
Denosumab biosimilar by Samsung Bioepis for Post Menopausal Osteoporosis: Likelihood of Approval
Denosumab biosimilar is under clinical development by Samsung Bioepis and currently in Phase III for Post Menopausal Osteoporosis.
Pharmaceutical Technology7h
LM-302 by Bristol-Myers Squibb for Esophageal Cancer: Likelihood of Approval
LM-302 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Esophageal Cancer. According to GlobalData, Phase I drugs for Esophageal Cancer have an 80% phase transition ...
Pharmaceutical Technology7h
Vemurafenib by F. Hoffmann-La Roche for Craniopharyngioma: Likelihood of Approval
Vemurafenib is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Craniopharyngioma. According to GlobalData, Phase II drugs for Craniopharyngioma does not have ...
Pharmaceutical Technology7h
Vemurafenib by F. Hoffmann-La Roche for Sarcomas: Likelihood of Approval
Vemurafenib is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Sarcomas. According to GlobalData, Phase II drugs for Sarcomas have a 27% phase transition success rate ...